Retatrutide vs tirzepatide: different pathways and status
Retatrutide and tirzepatide are both peptides that mimic the gut hormones regulating satiety and blood sugar, and both were developed by Eli Lilly. The difference lies in the number of receptors targeted: tirzepatide works on two receptors, GLP-1 and GIP, while Retatrutide adds a third receptor, glucagon. That is why Retatrutide is often called the next generation of the same family.
A summary of the differences
| Tirzepatide | Retatrutide | |
|---|---|---|
| Target receptors | GLP-1 and GIP | GLP-1, GIP, and glucagon |
| Nickname | Dual agonist | Triple agonist |
| Brand name | Mounjaro and Zepbound | Still uses the compound name |
| Development stage | On the market as a medicine in the United States since 2022, then Europe and many other countries | Phase 3 clinical trials (the TRIUMPH program) |
| Research focus | Blood sugar, body weight, sleep apnea | Body weight, liver fat, energy expenditure |
How tirzepatide works: two pathways at once
Tirzepatide binds to the GLP-1 and GIP receptors, two incretin hormones released by the gut after eating. GLP-1 helps release insulin in line with blood sugar levels, slows gastric emptying, and sends a fullness signal to the brain. GIP also strengthens the insulin response and plays a role in how the body stores and uses fat. The combination of these two pathways is what made tirzepatide stand out in metabolic research, until it finally reached the market as a type 2 diabetes medicine under the name Mounjaro and for weight management under the name Zepbound.
What Retatrutide adds through the glucagon receptor
Retatrutide carries the same two pathways, then adds the glucagon receptor. Glucagon is better known as the hormone that raises blood sugar, but in the liver and fat tissue it also promotes fat burning and energy expenditure. In the Retatrutide formulation, the effect of glucagon on blood sugar is balanced by GLP-1 and GIP, so what is put to use is its push toward energy expenditure.
The phase 2 clinical trial of Retatrutide published in the New England Journal of Medicine in June 2023 observed large weight loss over 48 weeks, and its follow-up analysis recorded that participants' liver fat levels also went down. This finding is what made Retatrutide so widely discussed, because its third pathway touches the energy-burning side, not only satiety.
Where the research on each stands now
Tirzepatide has passed through every stage of drug development. The SURPASS clinical trial program for diabetes and SURMOUNT for body weight became the basis of its marketing authorization in the United States since 2022, followed by Europe and many other countries.
Retatrutide is in the final stage. Since December 2025, Eli Lilly has begun reporting positive results from the phase 3 clinical trial program called TRIUMPH, and the next step is applying for marketing authorization as a medicine with the relevant authorities. While that process is under way, Retatrutide is available as a research material. An explanation of each stage of its development is in Retatrutide in Indonesia.
Retatrutide as a development of the same family
For those of you who already know tirzepatide, Retatrutide is easiest to understand as a development with one additional pathway. Its two incretin pathways are the same, while the glucagon pathway adds the energy expenditure side. Peptivia also offers Retatrutide paired with Cagrilintide, an amylin pathway peptide that also helps regulate satiety; the reasons the two are paired are covered in Retatrutide and Cagrilintide, and the amylin pathway itself is reviewed in Eloralintide and the amylin pathway.
Details of the vial sizes and package contents of Retatrutide and Retatrutide + Cagrilintide are in the Peptivia catalog. If there is anything you would like to ask before ordering, the Peptivia team is ready to help through Peptivia's official WhatsApp.